drugset
drugset / Trial / NCT02898207

Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer

NCT02898207 ↗

Phase 1 Completed 28 enrolled National Cancer Institute (NCI)
Non-randomizedSequentialOpen-labelTreatment

Summary

This phase I trial studies the side effects and best dose of olaparib and onalespib when given together in treating patients with solid tumors that have spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable) or ovarian, fallopian tube, primary peritoneal, or triple-negative breast cancer that has come back (recurrent). Olaparib and onalespib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start
2017-05-19
Primary completion
2020-07-29
Completion
2022-01-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Olaparib Small molecule 200 mg Oral
Subject Olaparib Small molecule 300 mg Oral
Subject Onalespib Small molecule 20 mg/m2 Intravenous
Subject Onalespib Small molecule 40 mg/m2 Intravenous
Subject Onalespib Small molecule 80 mg/m2 Intravenous
Subject Onalespib Small molecule 120 mg/m2 Intravenous

Indications

fallopian tube serous adenocarcinoma high grade malignant neoplasm metastatic malignant neoplasm ovarian serous adenocarcinoma primary peritoneal serous adenocarcinoma triple-negative breast carcinoma